These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

30 related articles for article (PubMed ID: 28181455)

  • 1. Limiting "evergreening" for a better balance of drug innovation incentives.
    Stanbrook MB
    CMAJ; 2013 Aug; 185(11):939. PubMed ID: 23877665
    [No Abstract]   [Full Text] [Related]  

  • 2. An empirical review of major legislation affecting drug development: past experiences, effects, and unintended consequences.
    Kesselheim AS
    Milbank Q; 2011 Sep; 89(3):450-502. PubMed ID: 21933276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Old drugs, new uses: solving a Hatch-Waxman patent predicament.
    McPhie DC
    Food Drug Law J; 2004; 59(1):155-68. PubMed ID: 15190929
    [No Abstract]   [Full Text] [Related]  

  • 4. Navigating the Hatch-Waxman Act's safe harbor.
    Jones PB
    Food Drug Law J; 2002; 57(3):475-89. PubMed ID: 12710407
    [No Abstract]   [Full Text] [Related]  

  • 5. An Administrative Meter Maid: Using Inter Partes Review and Post-Grant Review to Curb Exclusivity Parking via the "Failure to Market" Provision of the Hatch-Waxman Act.
    Apel BT
    Mich Law Rev; 2015; 114(1):107-36. PubMed ID: 26394458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is Noerr-Pennington immunity still a viable defense against antitrust claims arising from Hatch-Waxman litigation?
    Steinhauer EH
    Food Drug Law J; 2006; 61(4):679-700. PubMed ID: 17180769
    [No Abstract]   [Full Text] [Related]  

  • 7. Implications of
    Carson P; Cade A
    Pharm Pat Anal; 2019 May; 8(3):65-70. PubMed ID: 31179899
    [No Abstract]   [Full Text] [Related]  

  • 8. How Cuozzo will impact the interplay between post grant proceedings and Hatch-Waxman litigation.
    Mishra N; Doody PA; Davé RS
    Pharm Pat Anal; 2017 Jan; 6(1):9-15. PubMed ID: 28181455
    [No Abstract]   [Full Text] [Related]  

  • 9. Hatch-Waxman in the Federal Courts: from 1994--2004.
    Ludwig SP; Kosinski KB; Harris J
    Drug Dev Ind Pharm; 2005 Jan; 31(2):215-22. PubMed ID: 15773288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inter Partes Review: Patent Killer No More?
    Chen FC; Lee PS
    Trends Biotechnol; 2019 Jul; 37(7):680-683. PubMed ID: 30890272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Hatch-Waxman Act: encouraging innovation and generic drug competition.
    Sokal AM; Gerstenblith BA
    Curr Top Med Chem; 2010; 10(18):1950-9. PubMed ID: 20615183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Obtaining, challenging and enforcing pharmaceutical patents under the America Invents Act.
    Genieser LH; McCann CE
    Pharm Pat Anal; 2012 Sep; 1(4):415-26. PubMed ID: 24236880
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.